1 to 10 of 35 literature results

• Predicting the time of conversion to MCI in the elderly: role of verbal expression and learning.

  BACKGROUND: Increasing awareness that minimal or mild cognitive impairment (MCI) in the elderly may be a precursor of dementia has led to an increase …

  Authors: Abderrahim Oulhaj, Gordon K Wilcock, A David Smith, Celeste A de Jager

  Source: Neurology. 2009 Nov 3

  View Full Text

• TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease.

  Levels of tumor necrosis factor-alpha (TNF-alpha) are increased in the brain in Alzheimer's disease (AD). The TNF-alpha/TNF-R signaling pathways invol…

  Authors: Doris Culpan, Dougal Cram, Kate Chalmers, Abigail Cornish, Laura Palmer, Jennifer Palmer, Anthony Hughes, Peter Passmore, David Craigs, Gordon K Wilcock,…

  Source: Neurobiology of aging. 2009 Jul

  View Full Text

• Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

  Findings from longitudinal and cross-sectional studies suggest an association between high blood pressure and dementia, and in turn the use of antihyp…

  Authors: Patrick G Kehoe, Gordon K Wilcock

  Source: Lancet neurology. 2007 Apr

  View Full Text

• Premorbid effects of APOE on synaptic proteins in human temporal neocortex.

  APOE affects the risk of Alzheimer's disease (AD) and course of several other neurologic diseases. Experimental studies suggest that APOE influences s…

  Authors: Seth Love, L Khai Siew, David Dawbarn, Gordon K Wilcock, Yoav Ben-Shlomo, Shelley J Allen

  Source: Neurobiology of aging. 2006 Jun

  View Full Text

• Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.

  Cholinesterase inhibitors (ChEIs) are widely used for the symptomatic treatment of Alzheimer's disease (AD). In vitro and in animal studies, ChEIs hav…

  Authors: Katy A Chalmers, Gordon K Wilcock, Harry V Vinters, Elaine K Perry, Robert Perry, Clive G Ballard, Seth Love

  Source: Journal of neurology. 2009 May

  View Full Text

• Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

  BACKGROUND: The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of ta…

  Authors: Gordon K Wilcock, Sandra E Black, Suzanne B Hendrix, Kenton H Zavitz, Edward A Swabb, Mark A Laughlin, Tarenflurbil Phase II Study investigators

  Source: Lancet neurology. 2008 Jun

  View Full Text

• Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease.

  The levels of pro-inflammatory cytokines, such as tumour necrosis factor-alpha (TNF-alpha), are increased in the brain in Alzheimer's disease (AD). Mo…

  Authors: Doris Culpan, Abigail Cornish, Seth Love, Patrick G Kehoe, Gordon K Wilcock

  Source: Experimental gerontology. 2007 Jun

  View Full Text

• Memantine for the treatment of dementia.

  BACKGROUND: The use of cholinesterase inhibitors to correct the cholinergic deficit in patients with mild to moderate Alzheimer's disease (AD) is well…

  Authors: Gordon K Wilcock

  Source: Lancet neurology. 2003 Aug

  View Full Text

• Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease.

  The perineuronal net (PN), a specialised region of extracellular matrix, is interposed between the neuronal cell surface and astrocytic processes. It …

  Authors: Shabnam Baig, Gordon K Wilcock, Seth Love

  Source: Acta neuropathologica. 2005 Oct

  View Full Text

• Absence of Chlamydia pneumoniae in brain of vascular dementia patients.

  We recently detected cytomegalovirus (CMV) in brains of 83% of vascular dementia (VaD) patients and 34% of age-matched normal people. Since CMV and al…

  Authors: Matthew A Wozniak, Ann Cookson, Gordon K Wilcock, Ruth F Itzhaki

  Source: Neurobiology of aging. 2003 Oct

  View Full Text